Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers

Clinical Pharmacology and Therapeutics

Volumn 78, Issue 4, 2005, Pages 342-350

  Chung, Jae Yong ^a   Cho, Joo Youn ^a   Yu, Kyung Sang ^a   Kim, Jung Ryul ^a   Oh, Dal Seok ^a   Jung, Hye Ryung ^a   Lim, Kyoung Soo ^a   Moon, Ki Ho ^a   Shin, Sang Goo ^a   Jang, In Jin ^a,b  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B1; PITAVASTATIN; PITAVASTATIN LACTONE; POLYPEPTIDE; UNCLASSIFIED DRUG;

ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; GENETIC VARIABILITY; GENOTYPE; HEALTH STATUS; HUMAN; KOREA; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

ADULT; ALLELES; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; DOSE-RESPONSE RELATIONSHIP, DRUG; GENOTYPE; HALF-LIFE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KOREA; MALE; ORGANIC ANION TRANSPORTERS; QUINOLINES;

EID: 25844530136     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2005.07.003     Document Type: Article

References (18)

1. T. Aoki, H. Nishimura, S. Nakagawa, J. Kojima, H. Suzuki, T. Tamaki Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3- methylglutaryl-coenzyme A reductase Arzneimittelforschung 47 1997 904 909
2. H. Fujino, I. Yamada, S. Shimada, T. Nagao, M. Yoneda Metabolic fate of pitavastatin (NK-104), a new inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase. Effects on drug-metabolizing systems in rats and humans Arzneimittelforschung 52 2002 745 753
3. H. Fujino, I. Yamada, S. Shimada, M. Yoneda, J. Kojima Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase human UDP- glucuronosyltransferase enzymes involved in lactonization Xenobiotica 33 2003 27 41
4. J. Kojima, H. Fujino, H. Abe, M. Yosimura, H. Kanda, H. Kimata Identification of metabolites of NK-104, an HMG-CoA reductase inhibitor, in rat, rabbit and dog bile Biol Pharm Bull 22 1999 142 150
5. K. Kajinami, H. Mabuchi, Y. Saito NK-104 a novel synthetic HMG-CoA reductase inhibitor Expert Opin Investig Drugs 9 2000 2653 2661
6. B. Hsiang, Y. Zhu, Z. Wang, Y. Wu, V. Sasseville, W.P. Yang A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters J Biol Chem 274 1999 37161 37168
7. M. Hirano, K. Maeda, Y. Shitara, Y. Sugiyama Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans J Pharmacol Exp Ther 311 2004 139 146
8. S.G. Simonson, A. Raza, P.D. Martin, P.D. Mitchell, J.A. Jarcho, C.D. Brown Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine Clin Pharmacol Ther 76 2004 167 177
9. R.G. Tirona, B.F. Leake, G. Merino, R.B. Kim Polymorphisms in OATP-C. Identification of multiple allelic variants associated with altered transport activity among European- and African-Americans J Biol Chem 276 2001 35669 35675
10. M. Niemi, E. Schaeffeler, T. Lang, M.F. Fromm, M. Neuvonen, C. Kyrklund High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1) Pharmacogenetics 14 2004 429 440
11. Y. Nishizato, I. Ieiri, H. Suzuki, M. Kimura, K. Kawabata, T. Hirota Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes consequences for pravastatin pharmacokinetics Clin Pharmacol Ther 73 2003 554 565
12. J. Mwinyi, A. Johne, S. Bauer, I. Roots, T. Gerloff Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics Clin Pharmacol Ther 75 2004 415 421
13. P. Iglesias, J.J. Diez New drugs for the treatment of hypercholesterolaemia Expert Opin Investig Drugs 12 2003 1777 1789
14. C.D.A. Brown, A. Windass, K. Bleasby, B. Lauffart Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C Atherosclerosis Suppl 2 2001 90
15. D. Nakai, R. Nakagomi, Y. Furuta, T. Tokui, T. Abe, T. Ikeda Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes J Pharmacol Exp Ther 297 2001 861 867
16. C.K. Hui, B.M. Cheung, G.K. Lau Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis Br J Clin Pharmacol 59 2005 291 297
17. M. Iwai, H. Suzuki, I. Ieiri, K. Otsubo, Y. Sugiyama Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C) Pharmacogenetics 14 2004 749 757
18. P. Mathew, T. Cuddy, W.G. Tracewell, D. Salazar An open-label study on the pharmacokinetics (PK) of pitavastatin (NK-104) when administered concomitantly with fenofibrate or gemfibrozil in healthy volunteers [abstract] Clin Pharmacol Ther 75 2004 P33